Novo A/S 13D and 13G filings for Reneo Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-12-15 4:55 pm Sale |
2023-12-14 | 13D | Reneo Pharmaceuticals, Inc. RPHM |
Novo A/S | 0 0.000% |
-343,038 (Position Closed) |
Filing |
| 2023-05-15 5:16 pm Unchanged |
2023-05-09 | 13D | Reneo Pharmaceuticals, Inc. RPHM |
Novo A/S | 343,038 10.200% |
0 (Unchanged) |
Filing |
| 2022-09-30 4:45 pm Unchanged |
2022-09-27 | 13D | Reneo Pharmaceuticals, Inc. RPHM |
Novo A/S | 343,038 14.000% |
0 (Unchanged) |
Filing |
| 2022-01-27 3:31 pm Unchanged |
2022-01-20 | 13D | Reneo Pharmaceuticals, Inc. RPHM |
Novo A/S | 343,038 14.000% |
0 (Unchanged) |
Filing |
| 2021-04-14 4:43 pm Purchase |
2021-04-08 | 13D | Reneo Pharmaceuticals, Inc. RPHM |
Novo A/S | 343,038 14.200% |
343,038 (New Position) |
Filing |